SAN FRANCISCO, Oct. 23, 2017 /PRNewswire/ -- Symic Bio, a biopharmaceutical company developing novel matrix regulators, today announced that the company will present at the following conferences.
Sofinnova Japan Biopharma Partnering Conference
Presenter: |
Ken Horne, Chief Executive Officer |
Date: |
Tuesday, Oct. 24, 2017 |
Time: |
9:55 a.m. JST |
Location: |
The Conrad Hotel, Tokyo |
BIO-Europe 2017 – 23rd Annual International Partnering Conference
Presenter: |
Rinko Ghosh, President and Chief Business Officer |
Date: |
Tuesday, Nov. 7, 2017 |
Time: |
4:15 p.m. CET |
Location: |
CityCube Berlin, Berlin |
About Symic Bio
Symic Bio is a biopharmaceutical company developing novel matrix regulators, a new category of therapeutics focused on matrix biology. These therapeutics, with potential applications in a wide variety of disease states, are inspired by naturally occurring macromolecules that play key regulatory roles within the extracellular matrix. Symic Bio currently has two clinical candidates: SB-030, which is targeting the prevention of peripheral vascular disease, and SB-061, directed at disease modification and pain management in the treatment of osteoarthritis. In addition, Symic Bio is investigating applications in the areas of fibrosis, oncology and diseases of the central nervous system. For additional information please visit the company's website at www.symic.bio, LinkedIn page at www.linkedin.com/company/symic-bio or follow on Twitter at www.twitter.com/symicbio.
SOURCE Symic Bio
Share this article